The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Patent No.:

US 9562069 B1

Date of Patent:

Feb. 07, 2017

Filed:

Jun. 17, 2014

Selective caspase inhibitors and uses thereof

Applicant:

Genesis Technologies Limited, Warrens, St. Michael, BB;

Inventors:

Jan-Eric Ahlfors, Laval, CA;

Khalid Mekouar, Laval, CA;

Assignee:

Other;

Attorney:

Knobbe, Martens, Olson & Bear, LLP

Primary Examiner:

David Lukton

Int. Cl.

CPC ...

C07K 5/08 (2006.01); C07K 5/10 (2006.01); C07K 5/062 (2006.01); C07C 271/22 (2006.01); C07C 317/50 (2006.01); C07D 209/16 (2006.01); C07D 213/81 (2006.01); C07D 215/12 (2006.01); C07D 295/26 (2006.01); C07F 9/40 (2006.01); C07F 9/6533 (2006.01); C07K 5/02 (2006.01); C07K 5/087 (2006.01); C07K 5/093 (2006.01); C07K 14/81 (2006.01); C07K 5/083 (2006.01); C07K 5/103 (2006.01); A61K 38/00 (2006.01); C07K 5/065 (2006.01); C07K 5/072 (2006.01); C07K 5/078 (2006.01);

U.S. Cl.

CPC ...

C07K 5/06034 (2013.01); C07C 271/22 (2013.01); C07C 317/50 (2013.01); C07D 209/16 (2013.01); C07D 213/81 (2013.01); C07D 215/12 (2013.01); C07D 295/26 (2013.01); C07F 9/4006 (2013.01); C07F 9/6533 (2013.01); C07K 5/0202 (2013.01); C07K 5/081 (2013.01); C07K 5/0812 (2013.01); C07K 5/0819 (2013.01); C07K 5/1013 (2013.01); C07K 14/8139 (2013.01); A61K 38/00 (2013.01); A61K 38/005 (2013.01); C07C 2102/08 (2013.01); C07K 5/06052 (2013.01); C07K 5/06078 (2013.01); C07K 5/06104 (2013.01); C07K 5/06139 (2013.01);

Abstract

The present invention relates to compounds of Formula I, IA, II, HA, III, or IHA and their pharmaceutical uses. Particular aspects of the invention relate to the use of those compounds for the selective inhibition of one or more caspases. Also described are methods where the compounds of Formula I, IA, II, IIA, III, or IIIA are used in the prevention and/or treatment of various diseases and conditions in subjects, including caspase-mediated diseases such as sepsis, myocardial infarction, ischemic stroke, spinal cord injury (SCI), traumatic brain injury (TBI) and neurodegenerative disease (e.g. multiple sclerosis (MS) and Alzheimer's, Parkinson's, and Huntington's diseases).

Find Patent Forward Citations